I believe that there are two very distinctive differences between DNDN's Provenge and NWBO's DCVax-L. The first is that Provenge, while effective, was quite costly and only slightly more effective than the available therapeutics while DCVax-L not only is a marked improvement on the SOC without supplementation with complementary therapeutics, but spectacularly more effective with them. The second is the DNDN didn't have an automatic way of making Provenge, while NWBO has the EDEN. DNDN went belly up on insufficient orders while I expect NWBO to be inundated with orders until EDEN's approved and sufficient units are available to deliver on the orders.
Provenge is available through a small, private company that took over, and no doubt they're still getting some orders, but it's not the new paradigm in treatment that DCVax-L will be and in time that should be true in many different cancers, not just GBM or brain cancers.
Gary
Market Data 
Markets 
AI
